SCHEMBL306391

SCHEMBL306391

[CH2]C(C)C(C)CCCCCC(C)C

nearest known ligand 0.46

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
KDM4C Q9H3R0 2/20 0.31
KDM4A O75164 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28972282 1.00 LMNA (0.46) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL14656811 0.97 LMNA (0.48) LMNA
SCHEMBL17607540 0.92 LMNA (0.48) LMNA
SCHEMBL5086519 0.81 OPRM1 (0.46) LMNA
SCHEMBL5613428 0.81 OPRM1 (0.46) LMNA
SCHEMBL5613268 0.81 OPRM1 (0.46) LMNA
SCHEMBL5090277 0.81 OPRM1 (0.46) LMNA
SCHEMBL5090691 0.81 OPRM1 (0.46) LMNA
SCHEMBL9211579 0.81 OPRM1 (0.46) LMNA
SCHEMBL5613655 0.81 OPRM1 (0.46) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132728-A1 Bio-Based Coalescing Solvents BATTELLE MEMORIAL INSTITUTE 2024-04-25 US disclosed
EP-4259731-A2 BIO-BASED COALESCING SOLVENTS Battelle Memorial Institute (US) 2023-10-18 EP disclosed
WO-2022132820-A2 BIO-BASED COALESCING SOLVENTS BATTELLE MEMORIAL INSTITUTE (US) 2022-06-23 WO disclosed
US-10551345-B2 Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis APPLIED BIOSYSTEMS, LLC (US) 2020-02-04 US disclosed
EP-2496615-B1 ENVIRONMENTALLY FRIENDLY COLORANT COMPOSITIONS AND LATEX PAINTS/COATINGS MOORE BENJAMIN & CO (US) 2019-09-18 EP disclosed
EP-1910458-B1 LATEX PAINT FILM RESISTANT TO ADVERSE EFFECTS OF WATER, AND COMPOSITIONS AND METHODS FOR MAKING SAME BENJAMIN MOORE&CO (US) 2018-02-21 EP disclosed
US-20180030237-A1 Environmentally Friendly Colorant Compositions and Latex Paints/Coatings COLUMBIA INSURANCE CO (US) 2018-02-01 US disclosed
US-20170356877-A1 POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLIED BIOSYSTEMS, LLC (US) 2017-12-14 US disclosed
US-9815961-B2 Environmentally friendly colorant compositions and latex paints/coatings COLUMBIA INSURANCE COMPANY (US) 2017-11-14 US disclosed
US-9744236-B2 Photolabile compounds THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-08-29 US disclosed
WO-2005044281-A1 BAICALIN AND ITS DERIVATIVES AS A TREATMENT FOR SARS CORONA VIRUS INFECTION OR OTHER RELATED INFECTIONS THE UNIVERSITY OF HONG KONG (CN) 2005-05-19 WO disclosed
US-6864261-B2 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2005-03-08 US disclosed
WO-2005019353-A2 COPOLYMER SURFACTANTS COLUMBIA INSURANCE COMPANY (US) 2005-03-03 WO disclosed
US-20050039635-A1 Copolymer surfactants BENJAMIN MOORE & CO. 2005-02-24 US disclosed
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides APPLIED BIOSYSTEMS, LLC 2005-02-03 US disclosed
WO-2004104054-A1 POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-12-02 WO disclosed
US-20040127501-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. (LU) 2004-07-01 US disclosed
WO-2004029044-A1 PYRIMIDINE COMPOUNDS AS THERAPEUTIC AGENTS EURO-CELTIQUE, S.A. (LU) 2004-04-08 WO disclosed
US-20040053914-A1 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. 2004-03-18 US disclosed
WO-2003093236-A1 1-(PYRID-2-YL)-PIPERAZINE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR INHIBITOR EURO-CELTIQUE, S.A. (LU) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053914-A1 Therapeutic agents useful for treating pain SMN1; SMN2, OPRM1, PSEN1 LMNA 918/4885KDM4C 3452/4885KDM4A 3412/4885
US-20040127501-A1 Therapeutic agents useful for treating pain CACNA1A, GRIN2A, HTT LMNA 745/4885KDM4C 3351/4885KDM4A 3835/4885
US-20050025741-A1 Copolymers with (meth)acrylamides; improved separation of polynucleotides POLI, PCNA, POLL LMNA 779/4885KDM4C 4030/4885KDM4A 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.